Three conditions that disproportionately affect women share a common mechanism: endothelial dysfunction and impaired microvascular circulation. EECP — the same FDA-cleared therapy used for heart disease — directly addresses this root cause.
Fibromyalgia, lupus, scleroderma, Raynaud's syndrome, and related autoimmune conditions share a vascular signature: the endothelium — the single-cell lining of every blood vessel — is damaged, inflamed, or dysfunctional. This impairs nitric oxide production, reduces microvascular perfusion, and triggers the pain, fatigue, and temperature sensitivity that define these conditions.
EECP works by generating rhythmic pulsatile shear stress — the same mechanical force that healthy arteries use to maintain endothelial function. This triggers a cascade of vascular repair: nitric oxide release, endothelial progenitor cell mobilization, collateral vessel growth, and reduced systemic inflammation. The same mechanism that makes EECP effective for heart disease makes it relevant for these women's health conditions.
Each guide covers the condition's vascular mechanism, the clinical evidence for EECP, what to expect from treatment, and how to find a provider who offers it.
Microvascular dysfunction, central sensitization, and why improved blood flow reduces pain
How EECP addresses the endothelial dysfunction shared by lupus, scleroderma, and RA
Episodic vasospasm, sympathetic overactivation, and EECP's direct mechanism of action
Use the EECPLocator directory to find providers who offer EECP for off-label conditions including fibromyalgia, autoimmune disease, and Raynaud's syndrome. Filter by "Off-label treatment" to narrow results.
Find a Provider Near Me →Free Patient Guide — Women's Vascular Health
8 modules covering what EECP is, who it helps, how to find the right provider, and what to expect — including a section on EECP for fibromyalgia and autoimmune vascular conditions.